Evonik Commits $100M to Modernize Tippecanoe Labs in Lafayette

Evonik announced on July 8 a $100 million, five-year investment to modernize its Tippecanoe Labs site in Shadeland (Tippecanoe County), one of the world's largest active pharmaceutical ingredient facilities and Evonik's second-largest North American site, protecting more than 650 jobs. The move is part of a deliberate shift of assets from Europe to North America; Evonik sold its Hanau, Germany pharmaceutical ingredients business in June and is reinvesting the proceeds here. It's also timed to Section 232 pharmaceutical tariffs, effective July 31 for Annex III companies, that impose a default 100% charge on patented drug APIs unless the sponsor files an approved onshoring plan for a reduced 20% rate. If your API or specialty-chemical suppliers are going through the same European rationalization, your lead times and allocation priorities may already be tightening.